Francesca Ugo
6 Papers
8 Citations
Francesca Ugo is an academic researcher. The author has contributed to research in topics: Medicine & Pemetrexed. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).
Maria Carmela Piccirillo,Quincy Chu,Penelope A. Bradbury,Wei Tu,Courtney H. Coschi,Federica Grosso,Marie Florescu,Manlio Mencoboni,John R. Goffin,Maria Pagano,Fortunato Ciardiello,F.L. Cecere,Mark Vincent,Roberto Ferrara,David E. Dawe,Desiree Hao,Christopher W. Lee,Alessandro Morabito,Cesare Gridelli,Luigi Cavanna,Mussawar Iqbal,Normand Blais,Natasha B. Leighl,Paul Wheatley-Price,Ming-Sound Tsao,Francesca Ugo,Hazem E El-Osta,Piera Gargiulo,Pierre Olivier Gaudreau,Dongsheng Tu,Joana Sederias,P. Brown-Walker,Francesco Perrone,Lesley Seymour,Scott A. Laurie +34 more
TL;DR: The IND.227 trial as discussed by the authors compared progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro) versus pembro.
13
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM).
Diego Cortinovis,Lital Hollander,Irene Floriani,Federica Grosso,Alessandro Marinello,Giovanni Luca Ceresoli,Ilaria Pacchetti,Paolo Andrea Zucali,Maurizio D'Incalci,Stefania Canova,Maria Ida Abbate,Francesca Ugo,Suela Vukcaj,Paolo Bidoli +13 more
TL;DR: This data indicates that the use of Trabectedin (T) in MPM is a viable treatment option for patients with sarcomatoid/biphasic histotypes with dismal prognosis.
6
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
Federica Grosso,Francesco Gelsomino,Giulia Pasello,Lore Carlucci,Francesca Bono,Diego Cortinovis,D. Cortinovis,Stefania Canova,Francesca Colonese,Maria Ida Abbate,Luca Sala,Ernest Sala,M. Perez Gila,Fabio Pagni,Giovanni Luca Ceresoli,Alessandro D'Aveni,Maria Bonomi,Antonina M. De Angelis,Francesca Ugo,M. Belletti,Paolo Andrea Zucali,Matteo Perrino,Fabio De Vincenzo,Ana Luiza Roscoe Santoro,Andrea Ardizzoni,Stefano Frega,Manlio Mencoboni,Irene De Simone,Maurizio D'Incalci,Francesca Galli,Davide Poli,Erica Rulli,Vamsee Torri +32 more
TL;DR: DIADEM as discussed by the authors was a multicenter, open-label, single-arm, phase II trial aimed at evaluating the efficacy and safety of durvalumab for mesothelioma patients.
3
Trabectedin (T) as second line treatment option for patients with epithelioid malignant pleural mesothelioma (MPM) in progression following pemetrexed/platin-derivates chemotherapy: ATREUS trial.
Diego Cortinovis,Lital Hollander,Luciano Carlucci,Federica Grosso,Giovanni Luca Ceresoli,Ilaria Pacchetti,Paolo Andrea Zucali,Maurizio D'Incalci,Marcello Tiseo,Lorenzo Legramandi,Stefania Canova,Francesca Ugo,Maria Ida Abbate,Giacomo Taverna,Viola Cogliati,Paolo Bidoli +15 more
TL;DR: Systemic chemotherapy in MPM is inevitably followed by relapse, and response rates to second line treatment are limited, so patients need to be prepared for further treatment with a second line agent.
3
[The organization and staff of a centralized Clinical Trial Center: the Alessandria model.]
TL;DR: The case study refers to the Clinical Trial Center of the Public Hospital "SS. Antonio e Biagio and Cesare Arrigo" and the Local Health Authority of Alessandria, which is unique in the regional panorama and a rarity into a public health organization not recognized as Scientific Institute for Research, Hospitalization and Healthcare (IRCCS).